Tumor-selective Anticancer Prodrugs

肿瘤选择性抗癌前药

基本信息

  • 批准号:
    6552125
  • 负责人:
  • 金额:
    $ 12.88万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2002
  • 资助国家:
    美国
  • 起止时间:
    2002-09-16 至 2003-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The proteolytic activity of matrix metalloproteases (MMPs)-2 and -9 is highly localized to the outer surfaces of invasive tumors. The goal of this project is to synthesize and evaluate prodrugs that are selectively cleaved by MMP-2 and -9 at the tumor site. Using both direct attachment and cleavable linkers, we will synthesize derivatives of two classes of antitumor compounds, the amino secocyclopropylbenzindolines (CBls) and doxorubicin, to which short MMP-cleavable peptides are appended. The CBIs are an extraordinarily potent class of minor groove binding/alkylating agents that show in vitro cytotoxicity at picomolar concentrations. Doxorubicin, white 1000-fold less potent in vitro, is a clinically approved drug having a well-described therapeutic profile against many hematologic and solid tumors. Our strategy takes advantage of the highly regulated, tumor-restricted proteotytic activity of MMPs-2 and -9, and the high turnover rates of these enzymes. We plan to demonstrate through our in vitro enzymatic assays, in vitro cytotoxicity assays, and in vivo therapy experiments, that MMP-substrate peptidyl prodrugs will have attenuated toxicities compared to their corresponding parent drugs, tumor selectivity, and therapeutic efficacy for the treatment of cancer. PROPOSED COMMERCIAL APPLICATION: Cancer therapy still represents one of the largest unmet medical needs. The goal of many prodrug strategies is to increase the amount of active drug delivered to a tumor through selective activation pathways. The prodrugs we propose are designed to be significantly less toxic until reactivated at the tumor site by tumor-selective enzymatic activity. this strategy could represent a significant advancement toward the goal of distinguishing between normal and malignant cells, and, as such, a significant advancement in the treatment of cancer.
描述(申请人提供):基质金属蛋白水解酶(MMPs)-2和-9高度定位于侵袭性肿瘤的外表面。该项目的目标是合成和评估在肿瘤部位选择性地被基质金属蛋白酶-2和-9切割的前药物。利用直接连接物和可裂解连接物,我们将合成两类抗肿瘤化合物的衍生物,即氨基二环丙基苯并吲哚(CBLS)和阿霉素,并在其上附加可裂解的短肽。CBIS是一类非常有效的微小沟槽结合/烷基化试剂,在皮摩尔浓度下显示出体外细胞毒性。阿霉素在体外的效力是白色的1000倍,是一种临床批准的药物,对许多血液和实体肿瘤具有良好的治疗效果。我们的策略利用了MMPs-2和MMPs-9高度调控、肿瘤受限的蛋白分解活性,以及这些酶的高周转率。我们计划通过我们的体外酶分析、体外细胞毒性分析和体内治疗实验来证明,与相应的母体药物相比,基质金属蛋白酶底物多肽前药具有减轻毒性、肿瘤选择性和治疗癌症的疗效。 拟议的商业应用:癌症治疗仍然是最大的未得到满足的医疗需求之一。许多前药策略的目标是通过选择性激活途径增加给肿瘤的活性药物的量。我们建议的前药设计为毒性显著降低,直到肿瘤部位通过肿瘤选择性酶活性重新激活。这一策略可能代表着朝着区分正常细胞和恶性细胞的目标迈进了一大步,也因此在癌症治疗方面取得了重大进步。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Toni KLINE其他文献

Toni KLINE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Toni KLINE', 18)}}的其他基金

Antibiotic Drug Discovery
抗生素药物发现
  • 批准号:
    8236979
  • 财政年份:
    2011
  • 资助金额:
    $ 12.88万
  • 项目类别:
Antibiotic Drug Discovery
抗生素药物发现
  • 批准号:
    7675846
  • 财政年份:
    2009
  • 资助金额:
    $ 12.88万
  • 项目类别:
Medicinal Chemistry
药物化学
  • 批准号:
    7639081
  • 财政年份:
    2008
  • 资助金额:
    $ 12.88万
  • 项目类别:
SYNTHETIC ANTAGONISTS OF THE PSEUDOMONAS AUTOINDUCER
假单胞菌自诱导剂的合成拮抗剂
  • 批准号:
    2712395
  • 财政年份:
    1998
  • 资助金额:
    $ 12.88万
  • 项目类别:
Antibiotic Drug Discovery
抗生素药物发现
  • 批准号:
    8377658
  • 财政年份:
  • 资助金额:
    $ 12.88万
  • 项目类别:
Antibiotic Drug Discovery
抗生素药物发现
  • 批准号:
    8051659
  • 财政年份:
  • 资助金额:
    $ 12.88万
  • 项目类别:
Antibiotic Drug Discovery
抗生素药物发现
  • 批准号:
    8447083
  • 财政年份:
  • 资助金额:
    $ 12.88万
  • 项目类别:

相似海外基金

RII Track-4:NSF: In-vitro Cytotoxicity Assessment of Synthesized Quantum Dots for Enhanced Cell Imaging
RII Track-4:NSF:用于增强细胞成像的合成量子点的体外细胞毒性评估
  • 批准号:
    2327429
  • 财政年份:
    2024
  • 资助金额:
    $ 12.88万
  • 项目类别:
    Standard Grant
Impact of Obesity on Chemotherapy-Induced Cytotoxicity: Immune Cells and Skeletal Muscle
肥胖对化疗引起的细胞毒性的影响:免疫细胞和骨骼肌
  • 批准号:
    10572695
  • 财政年份:
    2023
  • 资助金额:
    $ 12.88万
  • 项目类别:
Cytotoxicity and function of incomplete proteins
不完整蛋白质的细胞毒性和功能
  • 批准号:
    10570685
  • 财政年份:
    2023
  • 资助金额:
    $ 12.88万
  • 项目类别:
Alpha-Synuclein aberrantly modifies the nanoscale distribution and function of ion channels to promote neuronal cytotoxicity
α-突触核蛋白异常地改变离子通道的纳米级分布和功能以促进神经元细胞毒性
  • 批准号:
    10635208
  • 财政年份:
    2023
  • 资助金额:
    $ 12.88万
  • 项目类别:
SBIR Phase I: Antibody Therapy that Targets Neoantigens in Acute Myeloid Leukemia via the Antibody Dependent Cell-mediated Cytotoxicity Mechanism of Natural Killer Cells
SBIR 第一期:通过抗体依赖性细胞介导的自然杀伤细胞的细胞毒性机制,针对急性髓性白血病新抗原的抗体疗法
  • 批准号:
    2246487
  • 财政年份:
    2023
  • 资助金额:
    $ 12.88万
  • 项目类别:
    Standard Grant
NK Cell Cytotoxicity Against Cryptococcus neoformans in Persons with Advanced HIV and Cryptococcal Meningitis
NK 细胞对晚期 HIV 和隐球菌性脑膜炎患者的新型隐球菌的细胞毒性
  • 批准号:
    10543405
  • 财政年份:
    2022
  • 资助金额:
    $ 12.88万
  • 项目类别:
Investigating the role of Cdk5 and p35 in natural killer cell cytotoxicity
研究 Cdk5 和 p35 在自然杀伤细胞细胞毒性中的作用
  • 批准号:
    10701749
  • 财政年份:
    2022
  • 资助金额:
    $ 12.88万
  • 项目类别:
Antibody dependent cellular cytotoxicity and HIV-1 mother to child transmission
抗体依赖性细胞毒性和 HIV-1 母婴传播
  • 批准号:
    10707299
  • 财政年份:
    2022
  • 资助金额:
    $ 12.88万
  • 项目类别:
Co-Evolution Mechanisms of Pre-Cancer-Immune Interactions in Shaping Adaptive Cytotoxicity and Myeloid-Derived Suppression
形成适应性细胞毒性和骨髓源性抑制的癌前免疫相互作用的共同进化机制
  • 批准号:
    10518849
  • 财政年份:
    2022
  • 资助金额:
    $ 12.88万
  • 项目类别:
Optogenetic interrogation of TDP-43 cytotoxicity
TDP-43 细胞毒性的光遗传学研究
  • 批准号:
    22H02958
  • 财政年份:
    2022
  • 资助金额:
    $ 12.88万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了